EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
The refocused commercial set-up will increase organizational efficiency and alignment across all commercial functions globally
Subscribe To Our Newsletter & Stay Updated